Sensorion prepares US listing and files with the SEC
The French biotech company has filed a draft registration document with the American regulator, the first formality of a potential listing on the other side of the Atlantic.
A document filed confidentially with the SEC
Sensorion (FR001401A9Z0 - ALSEN), a clinical-stage biotechnology company specializing in the development of therapies to restore hearing and treat hearing loss disorders, announced on September 16, 2026 that it has confidentially submitted a draft registration document on Form F-1 to the Securities and Exchange Commission (SEC), the regulator of American financial markets.
This confidential submission constitutes a preliminary step in the company's evaluation of a possible initial public offering in the United States of its ordinary shares.
An ADS listing being considered, subject to market conditions
The contemplated transaction could take the form of American Depositary Shares (ADS) and result in a listing of these ADS on a US national marketplace, subject to market conditions and other conditions.
The company specifies that this press release does not constitute an offer to sell or a solicitation to buy securities and that it is being disseminated in compliance with Rule 135 of the Securities Act of 1933.
